TheraBionic device for advanced hormone-positive breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a device called TheraBionic P1, which uses low-level radiofrequency energy to treat advanced breast cancer that has stopped responding to standard treatments. It may offer a new option for people who have exhausted other therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 22 or older.
- Your breast cancer is hormone receptor-positive and HER2-negative, meaning it grows in response to hormones and lacks a specific protein.
- Your cancer is advanced or has spread, and you have already tried at least one hormone therapy with a CDK4/6 inhibitor and one chemotherapy or antibody-drug conjugate.
- You are expected to live at least 3 more months and are able to care for yourself (ECOG score 0-2).
- You are not pregnant or breastfeeding, and you agree to use effective contraception if you could become pregnant.
- You do not have active mouth sores, ulcers, or other mouth conditions that could interfere with using the device.
- You are not taking calcium channel blockers (like amlodipine or nifedipine) or vitamin C supplements, or you are willing to stop them at least one day before treatment.
- You are not allergic to nickel.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a device called TheraBionic P1, which uses low-level radiofrequency energy, for women with early-stage hormone receptor-positive, HER2-negative breast cancer. It is given before surgery to see if it can help shrink the tumor.
This trial tests a new combination of two immunotherapy drugs (Bria-IMT and a checkpoint inhibitor) against your doctor's choice of standard treatments. It is for people with advanced breast cancer that has spread and who have already tried several prior therapies.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This trial tests a device called TheraBionic P1 for people with advanced liver cancer that has not responded to other treatments. It may be an option if you have tried at least two prior therapies or cannot take standard treatments.
This trial tests a new device called TheraBionic P1 for patients with metastatic triple-negative breast cancer who have already tried at least two other treatments without success. The device is non-invasive and may help slow cancer growth.
This study tests a new device (a neuroprosthesis) placed during breast reconstruction to see if it can reduce long-term pain after a mastectomy. If you are having both breasts removed and plan to get tissue expander reconstruction, you may be able to join.
Hear when a new HER2-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.